WARNING LETTER - March 31, 2026 - Lovega LLC dba Pink Pony Peptides (721088)

Oct 13, 2026

Upload by OmBimo

A U.S. FDA warning letter dated March 31, 2026 addresses Lovega LLC dba Pink Pony Peptides (recipient Susan Vega) and identifies products “GLP-2 TZ,” “GLP-3 RT,” and “Bacteriostatic Water” offered for sale on the firm’s website. FDA states the products are unapproved new drugs under the FD&C Act because they are intended for human use despite labeling such as “laboratory research purposes only” and “Not for human consumption.” The letter alleges violations of sections 301(d) and 505(a) and notes no approved FDA applications are in effect for these products.

LanguageEnglish

CategoryLetters

FormatPDF

Pages21

Reading Time7 min

AccessFree to download

Overview

Date, Recipient, and Reference Number

FDA Findings

Unapproved new drug status and intended human use

Specific product examples from labeling

Legal Basis and Violations

FD&C Act sections 301(d) and 505(a)

Conclusion

WARNING LETTER Lovega LLC dba Pink Pony Peptides MARCS-CMS 721088 — MARCH 31, 2026 􀂫 More Warning Letters (/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters) Delivery Method: Via Email Product: Drugs Recipient: Susan Vega Lovega LLC dba Pink Pony Peptides 9314 Forest Hill Blvd 902 Wellington, FL 33411 United States 􀃓 [help@pinkponypeptides.com](help@pinkponypeptides.com) ([mailto:help@pinkponypeptides.com](mailto:help@pinkponypeptides.com) ) Issuing Ofﬁce: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER March 31, 2026 RE: 721088 Susan Vega: This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at [https://pinkponypeptides.com/ in December 2025. The](https://pinkponypeptides.com/ in December 2025. The) FDA has observed that your website offers “GLP-2 TZ,”“GLP-3 RT,” and “Bacteriostatic Water” (hereinafter Pink Pony Peptides products) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) . As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a) . Feedback [https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lovega-llc-dba-pink-pony-peptides-721088-03312026](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lovega-llc-dba-pink-pony-peptides-721088-03312026) 1/3 4/14/26 , 11:34 AM Lovega LLC dba Pink Pony Peptides-721088-03/31/2026 | FDA These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions. Despite statements on your product labeling marketing your products for “laboratory research purposes only” and “[n]ot for human consumption,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as deﬁned by section 201(g)(1) of the FD&C Act 21, U.S.C. 321(g)(1) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as deﬁned in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following: GLP-2 TZ On the webpage [https://pinkponypeptides.com/product/glp2/:](https://pinkponypeptides.com/product/glp2/:) “As a dual GIP and GLP-1 receptor agonist, Tirzepatide helps: o . . . Reduce appetite and increase satiety o . . . Enhance insulin sensitivity and glucose control o . . . Curb cravings without harsh stimulants o Support fat loss over time with clinical precision Originally developed for type 2 diabetes, Tirzepatide has rapidly become a favorite among physicians and wellness experts for its dramatic body recomposition results and long-lasting appetite regulation.” GLP-3 RT On the webpage [https://pinkponypeptides.com/product/glp3/:](https://pinkponypeptides.com/product/glp3/:) “As a GIP, GLP-1, and glucagon receptor agonist, Retatrutide offers three times the fat-ﬁghting horsepower in one clean, clinical ride. This cutting-edge peptide has shown jaw-dropping results in clinical trials — helping the body torch fat, suppress appetite, regulate blood sugar, and even improve metabolic function better than its singlepathw

FAQs

What action did the FDA take and when did it occur?

The FDA reviewed the recipient’s website in December 2025 and issued the warning letter on March 31, 2026.

Which products did the FDA identify for sale on the website?

FDA cited “GLP-2 TZ,” “GLP-3 RT,” and “Bacteriostatic Water” as being offered for sale in the United States.

Why does FDA consider the products unapproved new drugs?

FDA states the products are intended for human use and are not generally recognized as safe and effective (GRASE), and no approved applications are in effect under section 505(a).

What legal violations does the warning letter cite?

The letter states that introducing or delivering these unapproved new drugs for interstate commerce violates sections 301(d) and 505(a) of the FD&C Act.

Oct 13, 2026

Upload by OmBimo